Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Antibody responses of Macaca fascicularis against a new inactivated polio vaccine derived from Sabin strains (sIPV) in DTaP-sIPV vaccine.

Sato Y, Shiosaki K, Goto Y, Sonoda K, Kino Y.

Biologicals. 2013 May;41(3):184-9. doi: 10.1016/j.biologicals.2012.12.004. Epub 2013 Jan 30.

PMID:
23375165
2.
3.

Duration of neutralizing antibody titer after Japanese encephalitis vaccination.

Abe M, Okada K, Hayashida K, Matsuo F, Shiosaki K, Miyazaki C, Ueda K, Kino Y.

Microbiol Immunol. 2007;51(6):609-16.

4.

Immunological equivalence between mouse brain-derived and Vero cell-derived Japanese encephalitis vaccines.

Abe M, Shiosaki K, Hammar L, Sonoda K, Xing L, Kuzuhara S, Kino Y, Holland Cheng R.

Virus Res. 2006 Nov;121(2):152-60. Epub 2006 Sep 1.

PMID:
16815584
5.

Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.

Eda Y, Takizawa M, Murakami T, Maeda H, Kimachi K, Yonemura H, Koyanagi S, Shiosaki K, Higuchi H, Makizumi K, Nakashima T, Osatomi K, Tokiyoshi S, Matsushita S, Yamamoto N, Honda M.

J Virol. 2006 Jun;80(11):5552-62.

6.

[Mandatory postgraduate training in psychiatry in Yokohama City University and the affiliated medical facilities under the new system of postgraduate clinical education in Japan].

Sato R, Kawanishi C, Shiosaki K, Sugiyama N, Fujiwara S, Ozawa A, Odawara T, Hirayasu Y.

Seishin Shinkeigaku Zasshi. 2005;107(8):841-5. Japanese. No abstract available.

PMID:
16350308
7.

Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine.

Takeda S, Shiosaki K, Kaneda Y, Nakasatomi T, Yoshizaki H, Someya K, Konno Y, Eda Y, Kino Y, Yamamoto N, Honda M.

Clin Immunol. 2004 Jul;112(1):92-105.

PMID:
15207786
8.

trans-2,6-,3,6- and 4,6-diaza-5,6,6a,7,8,12b-hexahydro-benzo[c]phenanthrene-10,11- diols as dopamine agonists.

Gu YG, Bayburt EK, Michaelides MR, Lin CW, Shiosaki K.

Bioorg Med Chem Lett. 1999 May 17;9(10):1341-6.

PMID:
10360732
9.

Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.

Pearce RK, Jackson M, Britton DR, Shiosaki K, Jenner P, Marsden CD.

Psychopharmacology (Berl). 1999 Feb;142(1):51-60.

PMID:
10102782
10.

Microencapsulation of hepatitis B core antigen for vaccine preparation.

Uchida T, Shiosaki K, Nakada Y, Fukada K, Eda Y, Tokiyoshi S, Nagareya N, Matsuyama K.

Pharm Res. 1998 Nov;15(11):1708-13.

PMID:
9833992
11.

Fine structure of hepatitis B virus surface antigen produced by recombinant yeast: comparison with HBsAg of human origin.

Yamaguchi M, Sugahara K, Shiosaki K, Mizokami H, Takeo K.

FEMS Microbiol Lett. 1998 Aug 15;165(2):363-7.

12.

Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide.

Shen Y, Sullivan T, Lee CM, Meri S, Shiosaki K, Lin CW.

Brain Res. 1998 Jun 15;796(1-2):187-97.

PMID:
9689469
13.

Expression, release, and regulation of human TNF alpha from stable transfectants of HEK-293 cells.

Glaser KB, Falduto M, Metzger R, Pederson T, Pease L, Shiosaki K, Morgan DW.

Inflamm Res. 1997 Aug;46 Suppl 2:S127-8. No abstract available.

PMID:
9297544
14.
15.

Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.

Michaelides MR, Hong Y, DiDomenico S Jr, Bayburt EK, Asin KE, Britton DR, Lin CW, Shiosaki K.

J Med Chem. 1997 May 23;40(11):1585-99.

PMID:
9171869
16.
17.

Minor structural differences in Boc-CCK-4 derivatives dictate affinity and selectivity for CCK-A and CCK-B receptors.

Shiosaki K, Lin CW, Kopecka H, Bianchi B, Miller T, Stashko M, Witte D.

J Med Chem. 1997 Mar 28;40(7):1169-72.

PMID:
9089338
19.

Father-to-mother-to-infant transmission of HIV-1: clonally transmitted isolate of infant mutates more rapidly than that of the mother and rapidly loses reactivity with neutralizing antibody.

Okamoto Y, Shiosaki K, Eda Y, Tokiyoshi S, Yamaguchi Y, Gojobori T, Hachimori T, Yamazaki S, Hondo M.

Microbiol Immunol. 1997;41(2):131-8.

20.

The presence of the complement cascade does not lead to neuronal cell death in primary hippocampal cultures.

Manelli AM, Cadman ED, Shiosaki K, Puttfarcken PS.

Brain Res Bull. 1997;42(3):187-93.

PMID:
8995328
21.

Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D1 receptor agonists A-86929 and ABT-431.

Shiosaki K, Asin KE, Britton DR, Giardina WJ, Bednarz L, Mahan L, Mikusa J, Nikkel A, Wismer C.

Eur J Pharmacol. 1996 Dec 19;317(2-3):183-90.

PMID:
8997599
22.

Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.

Blanchet PJ, Grondin R, Bédard PJ, Shiosaki K, Britton DR.

Eur J Pharmacol. 1996 Aug 1;309(1):13-20.

PMID:
8864687
23.

ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.

Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M.

J Pharmacol Exp Ther. 1996 Jan;276(1):150-60.

PMID:
8558425
25.

Tetrapeptide CCK-A agonists: effect of backbone N-methylations on in vitro and in vivo CCK activity.

Holladay MW, Kopecka H, Miller TR, Bednarz L, Nikkel AL, Bianchi BR, Witte DG, Shiosaki K, Lin CW, Asin KE, et al.

J Med Chem. 1994 Mar 4;37(5):630-5.

PMID:
8126703
26.
27.

Potent and selective inhibitors of an aspartyl protease-like endothelin converting enzyme identified in rat lung.

Shiosaki K, Tasker AS, Sullivan GM, Sorensen BK, von Geldern TW, Wu-Wong JR, Marselle CA, Opgenorth TJ.

J Med Chem. 1993 Feb 19;36(4):468-78.

PMID:
8474103
28.

Rhamnose moiety of phosphoramidon is not required for in vivo inhibition of endothelin converting enzyme.

Pollock DM, Shiosaki K, Sullivan GM, Opgenorth TJ.

Biochem Biophys Res Commun. 1992 Jul 31;186(2):1146-50.

PMID:
1497648
29.

Behavioral effects of A71623, a highly selective CCK-A agonist tetrapeptide.

Asin KE, Bednarz L, Nikkel AL, Gore PA Jr, Montana WE, Cullen MJ, Shiosaki K, Craig R, Nadzan AM.

Am J Physiol. 1992 Jul;263(1 Pt 2):R125-35.

PMID:
1636779
30.

Endothelin-converting enzymes.

Opgenorth TJ, Wu-Wong JR, Shiosaki K.

FASEB J. 1992 Jun;6(9):2653-9. Review.

PMID:
1612289
31.

Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N epsilon)-amide residues.

Shiosaki K, Lin CW, Kopecka H, Craig RA, Bianchi BR, Miller TR, Witte DG, Stashko M, Nadzan AM.

J Med Chem. 1992 May 29;35(11):2007-14.

PMID:
1375964
32.

Production of hepatitis B virion-like particles in yeast.

Shiosaki K, Takata K, Nishimura S, Mizokami H, Matsubara K.

Gene. 1991 Oct 15;106(2):143-9.

PMID:
1937046
33.

Boc-CCK-4 derivatives containing side-chain ureas as potent and selective CCK-a receptor agonists.

Shiosaki K, Lin CW, Kopecka H, Tufano MD, Bianchi BR, Miller TR, Witte DG, Nadzan AM.

J Med Chem. 1991 Sep;34(9):2837-42.

PMID:
1716682
34.

Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.

Lin CW, Shiosaki K, Miller TR, Witte DG, Bianchi BR, Wolfram CA, Kopecka H, Craig R, Wagenaar F, Nadzan AM.

Mol Pharmacol. 1991 Mar;39(3):346-51.

PMID:
1706470
35.

Development of CCK-tetrapeptide analogues as potent and selective CCK-A receptor agonists.

Shiosaki K, Lin CW, Kopecka H, Craig R, Wagenaar FL, Bianchi B, Miller T, Witte D, Nadzan AM.

J Med Chem. 1990 Nov;33(11):2950-2. No abstract available.

PMID:
1700123
36.

[Construction of a yeast strain that produces non-infective hepatitis B virion-like particles].

Shiosaki K, Hamada F, Matsubara K.

Tanpakushitsu Kakusan Koso. 1990 Oct;35(14):2665-70. Japanese. No abstract available.

PMID:
2267345
37.

A yeast system for stable expression of hepatitis B surface antigen.

Shiosaki K, Miyatsu Y, Takahara K, Mizokami H, Hamada F, Matsubara K.

J Biotechnol. 1990 Jun;14(3-4):411-22.

PMID:
1366913
38.

Identification of a novel alpha-amylase by expression of a newly cloned human amy3 cDNA in yeast.

Shiosaki K, Takata K, Omichi K, Tomita N, Horii A, Ogawa M, Matsubara K.

Gene. 1990 May 14;89(2):253-8.

PMID:
2197187
39.

The essential region for assembly and particle formation in hepatitis B virus surface antigen produced in yeast cells.

Araki K, Shiosaki K, Araki M, Chisaka O, Matsubara K.

Gene. 1990 May 14;89(2):195-201.

PMID:
2197186
40.
41.
42.

A novel type of human alpha-amylase produced in lung carcinoid tumor.

Tomita N, Horii A, Doi S, Yokouchi H, Shiosaki K, Higashiyama M, Matsuura N, Ogawa M, Mori T, Matsubara K.

Gene. 1989 Mar 15;76(1):11-8.

PMID:
2701942
43.

[Characterization of hepatitis B virus surface antigen produced in yeast].

Sugahara K, Yokote H, Shiosaki K, Adachi S, Miyata K, Miyatsu Y, Nozaki C, Mizokami H, Miake F, Hamada F.

Uirusu. 1987 Jun;37(1):111-20. Japanese. No abstract available.

44.

Alkylpyridines in surface waters, groundwaters, and subsoils of a drainage located adjacent to an oil shale facility.

Riley RG, Garland TR, Shiosaki K, Mann DC, Wildung RE.

Environ Sci Technol. 1981 Jun 1;15(6):697-701. doi: 10.1021/es00088a009. No abstract available.

PMID:
22299748

Supplemental Content

Loading ...
Support Center